ZNF844: A Promising Drug Target and Biomarker for the Treatment of Solid Tumors

Target Name: ZNF844

NCBI ID: G284391

ZNF844

Other Name(s): ZN844_HUMAN | Zinc finger protein 844 | zinc finger protein 844 | ZNF844 variant 1 | Zinc finger protein 844, transcript variant 1

ZNF844: A Promising Drug Target and Biomarker for the Treatment of Solid Tumors

Abstract:

ZNF844 is a small non-coding RNA molecule that has been identified as a potential drug target and biomarker for the treatment of solid tumors. ZNF844 has been shown to play a critical role in the regulation of cell growth, apoptosis, and angiogenesis, which are fundamental processes that contribute to tumor progression and the development of invasive and metastatic phenotypes. ZNF844 has also been shown to be expressed in various types of solid tumors, including lung, breast, and colorectal cancer. Therefore, ZNF844 may have a promising future as a drug target or biomarker for the treatment of solid tumors.

Introduction:

Solid tumors are one of the leading causes of cancer-related deaths worldwide. The development of invasive and metastatic phenotypes by tumor cells can result in a significant impact on patient outcomes. The regulation of cell growth, apoptosis, and angiogenesis is a critical process that Contributes to tumor progression and the development of invasive and metastatic phenotypes. ZNF844, a small non-coding RNA molecule, has been identified as a potential drug target and biomarker for the treatment of solid tumors.

ZNF844: A Potential Drug Target:

The identification of ZNF844 as a potential drug target is based on its role in the regulation of cell growth, apoptosis, and angiogenesis. ZNF844 has been shown to play a critical role in the regulation of cell cycle progression, including G1, S, G2, and M phases. It has also been shown to regulate cell apoptosis, which is a critical process that contributes to tumor regression and the development of a more indolent phenotype. In addition, ZNF844 has been shown to regulate angiogenesis, which is the process by which new blood vessels are formed to supply oxygen and nutrients to tumors. This process is critical for tumor growth and the development of invasive and metastatic phenotypes.

ZNF844 has also been shown to play a critical role in the regulation of cellular adhesion. Adhesion is the process by which cells stick together and form tissues. This process is critical for the development of tissues and organs and is also important for the regulation of embryonic development. ZNF844 has been shown to regulate the formation of tight junctions, which are a type of adhesion protein that helps to maintain the integrity of tissues and organs.

Biomarker Potential:

The identification of ZNF844 as a potential biomarker for the treatment of solid tumors is based on its expression in various types of solid tumors, including lung, breast, and colorectal cancer. ZNF844 has been shown to be expressed in these tumors and has been shown to play a critical role in their development and progression. This suggests that ZNF844 may be a useful biomarker for the diagnosis and treatment of solid tumors.

Drug Target Potential:

The identification of ZNF844 as a potential drug target is based on its role in the regulation of cell growth, apoptosis, and angiogenesis. ZNF844 has been shown to play a critical role in the regulation of cell cycle progression, including G1, S, G2, and M phases. It has also been shown to regulate cell apoptosis, which is a critical process that contributes to tumor regression and the development of a more indolent phenotype. In addition, ZNF844 has been shown to regulate angiogenesis, which is the process by which new blood vessels are formed to supply oxygen and nutrients to tumors. This process is critical for tumor growth and the development of invasive and metastatic phenotypes.

Conclusion:

ZNF844 is a small non-coding RNA molecule that has been identified as a potential drug target and biomarker for the treatment of solid tumors. ZNF844 has been shown to play a critical role in the regulation of cell growth, apoptosis, and angiogenesis, which are fundamental processes that contribute to tumor progression and the development of invasive and metastatic phenotypes. The identification of ZNF844 as a potential drug target and biomarker

Protein Name: Zinc Finger Protein 844

Functions: May be involved in transcriptional regulation

The "ZNF844 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF844 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets